adMare BioInnovations — Full Portfolio

Thryv Therapeutics is a clinical-stage biotechnology company developing selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias such as Long QT Syndrome and acquired cardiometabolic diseases.

BiotechHealthtechMedical Devices

PFPaul F. Truex(Chairman of the Board & Chief Executive Officer)inDebra OdinkinASAmy Sehnertin

Co-investorsAMAmzak HealthALAlexandriaCTCTI Life Sciences Fund L.P.LULumira Ventures

Thryv Therapeutics is a clinical-stage biotech developing precision-medicine treatments for genetic arrhythmia syndromes and acquired cardiometabolic diseases using selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).

BiotechDigital HealthMedical Devices

PFPaul F. Truex(Chairman of the Board & Chief Executive Officer)inDODebra Odink(President & Chief Development Officer)inASAmy Sehnert(Chief Medical Officer)inMKMatt Killeen(Chief Business Officer)in

BoardSDSaumya Das(Chief Scientific Advisor)

Co-investorsLULumira VenturesAMAmzak HealthCTCTI Life Sciences Fund L.P.FOFonds de solidarité FTQ

ADP provides cloud-based human capital management solutions that integrate payroll, HR, talent management, time and attendance, tax, and benefits administration for businesses globally.

Cloud ComputingEnterprise SoftwareHR TechSaaSRoseland, US

Co-investorsADADP VenturesBRBraemont CapitalVAValor Equity Partners

Domain Therapeutics is a clinical-stage biopharmaceutical company developing GPCR-targeting therapies to address unmet medical needs in immuno-oncology and inflammation.

BiotechDigital Health

Co-investors3B3B Future Health FundCTCTI Life Sciences Fund L.P.OMOmnes CapitalPAPanacea VentureSESeventure Partners

Epitopea develops off-the-shelf cancer vaccines targeting aberrantly expressed tumor-specific antigens using its proprietary CryptoMap platform.

AI & Machine LearningBiotechHealthtechMontreal, CA

CPClaude PerreaultPTPierre Thibault

Co-investorsADAdvent Life SciencesCACambridge Innovation CapitalCTCTI Life Sciences Fund L.P.FOFonds de solidarité FTQ

Portfolio company acquired by Novo Nordisk for $1.1B USD.

Co-investorsAMAmorChemGEGenesys CapitalJDJDRF T1D FundNENew Enterprise Associates (NEA)TATarnagulla VenturesAMAmgen Ventures+2 more

Riposte is a strategic agency specialized in the charitable, community and nonprofit sector, providing communication strategy and creative services to nonprofit organizations (OBNL).

Impact & Social GoodMarketing Tech

Yapla provides management and communication tools designed for nonprofits to streamline their daily operations and internal workflows.

FintechImpact & Social GoodSaaS

Pascal Jarryin